Antibody-drug Conjugates
7
3
3
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (7)
ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma
MA-CRC-II-016 SHR-1811
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcinoma Patients
Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression
Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC